XARACOLL 300mg Dose Cohort Experienced Less Pain and XARACOLL was Generally Well Tolerated with an Adverse Event Profile Comparable to the Current Prescribing Information Innocoll Pharmaceuticals
$125 million refinancing substantially improves Innocoll's liquidity, enabling further investment in pharmaceutical technology portfolio and growth plan Innocoll Biotherapeutics plc, a specialty pharmaceutical